Blood clots form through a rapid, multi-step process that starts within seconds of a blood vessel being damaged. Your body detects the injury, recruits specialized cell fragments called platelets to seal the gap, then reinforces that temporary seal with a tough protein mesh. The entire process involves dozens of proteins working in sequence, and it’s tightly controlled so clotting stays local to the wound rather than spreading through your bloodstream.
The First Response: Platelets Rush to the Wound
The moment a blood vessel tears or ruptures, the inner lining peels back and exposes the structural proteins underneath, particularly collagen. These proteins are normally hidden from your bloodstream, so their sudden appearance acts as an alarm signal. Platelets, tiny cell fragments circulating in your blood, begin sticking to the exposed surface almost immediately.
How platelets attach depends on how fast blood is flowing. In smaller vessels like arterioles, where blood moves quickly, platelets need help slowing down before they can grab hold. Long strands of a sticky protein called von Willebrand factor unfurl from the damaged surface and act like molecular speed bumps, catching passing platelets and letting them roll to a stop. In larger, slower-flowing vessels, platelets can bind directly to the collagen without that extra step.
Once a platelet sticks to the wound, it transforms. It shifts from a smooth disc into an elongated shape with spiky extensions, dramatically increasing its surface area. This activated platelet then releases chemical signals that recruit more platelets to the site. The new arrivals link to each other through bridges made of fibrinogen, a protein already dissolved in your blood plasma. Within minutes, a soft platelet plug covers the wound. This plug is enough to slow bleeding, but it’s fragile. It needs reinforcement.
The Coagulation Cascade: Building a Stronger Clot
While platelets are forming their initial plug, a parallel chemical chain reaction is firing up in the blood plasma around the injury. This is the coagulation cascade, a domino-like sequence of protein activations that ultimately produces a tough, insoluble mesh to stabilize the platelet plug.
The cascade has two entry points that converge on the same outcome. The primary trigger in most real injuries is the extrinsic pathway: damaged tissue releases a protein called tissue factor, which teams up with a clotting factor already circulating in blood. This pair kickstarts a chain of activations. The intrinsic pathway, which involves a separate set of clotting factors (including the ones missing in hemophilia), amplifies and sustains the process once it’s underway. Think of the extrinsic pathway as the ignition and the intrinsic pathway as the fuel that keeps the reaction going.
Both pathways converge at the same critical step: the activation of thrombin, an enzyme that does the cascade’s most important job.
How Thrombin Creates the Fibrin Mesh
Thrombin converts fibrinogen, a soluble protein floating freely in your blood, into fibrin. It does this by snipping off small pieces of the fibrinogen molecule, creating fibrin monomers. These monomers spontaneously link together through chemical attraction, first forming short chains called intermediate polymers, then aggregating into a dense, cross-linked mesh.
Thrombin is only directly involved in that first clipping step. After that, the fibrin molecules self-assemble, weaving through and around the platelet plug like rebar through concrete. A separate enzyme then cross-links the fibrin strands to make the mesh even more durable. The result is a stable, solid clot that can withstand the pressure of flowing blood while the vessel wall heals underneath.
What Keeps Clotting From Spreading
Your body produces clotting factors continuously, so there needs to be a strong braking system to prevent clots from growing beyond the injury site. Three natural anticoagulant proteins handle most of this work: protein C, protein S, and antithrombin. These molecules circulate in your blood at all times, acting as a counterbalance to the clotting factors. They deactivate key enzymes in the cascade so that clotting stays confined to the area of damage.
When these natural brakes are working properly, the procoagulant and anticoagulant forces stay in balance. Enough clotting occurs to stop bleeding, but not so much that a clot blocks the vessel entirely. Inherited deficiencies in any of these anticoagulant proteins shift the balance toward excessive clotting, raising the risk of dangerous clots forming in veins or arteries.
When Clots Form Where They Shouldn’t
The same process that saves your life after a cut can cause serious harm when it activates inappropriately inside an intact blood vessel. A framework developed in the 19th century and still used today identifies three broad triggers for these pathological clots: changes in blood flow, damage to the vessel wall, and changes in blood composition.
Sluggish blood flow is a common trigger. Sitting still for long hours on a flight, being immobilized after surgery, or having blood pool in varicose veins all slow circulation enough to let clotting factors accumulate locally and start the cascade. Vessel wall damage can come from atherosclerosis, where fatty plaques crack open and expose the same collagen and tissue factor that would normally only be seen in a wound. Changes in blood composition include inherited clotting disorders, hormonal shifts from pregnancy or birth control, cancer, and inflammatory conditions that increase clotting factor levels.
Most dangerous clots involve more than one of these triggers at the same time, which is why risk assessment often looks at the full picture rather than any single factor.
Arterial Clots vs. Venous Clots
Not all clots are the same. Where a clot forms in your circulatory system determines what it’s made of, how it behaves, and what kind of damage it can do.
Arterial clots, the kind responsible for heart attacks and most strokes, form in high-flow, high-pressure vessels. They tend to be rich in fibrin and platelets. In heart attack patients, extracted clots are roughly 60% fibrin, with the rest composed of platelets, red blood cells, cholesterol crystals, and white blood cells. The exact makeup varies depending on what triggered the clot: clots that form over a ruptured plaque in a coronary artery contain more fibrin than platelets, while clots over an eroded plaque tend to be platelet-dominant.
Venous clots, like those in deep vein thrombosis, form in slower-flowing veins where blood pools. These clots are packed mainly with red blood cells and fibrin, giving them a darker, jelly-like appearance sometimes called a “red clot.” They contain some platelets and white blood cells, but far fewer than arterial clots. Stroke-causing clots retrieved from brain arteries show a layered structure, with platelet-rich zones containing dense fibrin and white blood cells alternating with red blood cell-rich zones.
This difference in composition is one reason arterial and venous clots are treated with different medications. Antiplatelet drugs target the platelet-heavy arterial clots, while anticoagulants are the primary treatment for venous clots where the fibrin-and-red-blood-cell matrix is the main problem.
How the Body Breaks Clots Down
Clot formation is only half the story. Once a wound heals, the clot needs to be dissolved so the vessel can return to normal. Your body handles this through fibrinolysis, a process where an enzyme called plasmin chews through the fibrin mesh, breaking it into small fragments that get cleared from the bloodstream.
Plasmin is produced from an inactive precursor that’s actually woven into the clot itself as it forms, essentially building in the seeds of the clot’s eventual destruction. Signals from the healing vessel wall activate this precursor at the right time. This cleanup process typically takes days to weeks, depending on the size and location of the clot. When fibrinolysis doesn’t work efficiently, clots can persist and grow, potentially breaking loose and traveling to the lungs or brain.